Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etrumadenant + itraconazole
- Development stage
- Phase 1
- Lead developer
- Arcus Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Drug Description: Etrumadenant + itraconazole is an experimental combination of two small-molecule drugs: - Etrumadenant is an oral, small-molecule dual antagonist of adenosine A2a and A2b receptors, under evaluation mainly as an immuno-oncology agent to counteract adenosine-mediated immunosuppression in the tumor microenvironment. - Itraconazole is a triazole antifungal agent, orally bioavailable, that inhibits fungal ergosterol synthesis and is known to inhibit CYP3A4 and Hedgehog signaling. This combination does not represent a marketed product or established therapeutic regimen, but each component can affect the metabolism and efficacy of the other due to itraconazole's strong CYP3A4 inhibition. There is no evidence in the provided sources or the clinical literature to suggest the combination has been studied or developed for a specific indication, and it is not an established pharmaceutical product.
- Other names
- AB928 + itraconazole
02
Targets
ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)ADORA2B (Adenosine A2B receptor)ADORA3 (Adenosine A3 receptor)CYP51A1 (Sterol 14α-demethylase)
Beyond the preview
Go deeper on etrumadenant + itraconazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etrumadenant + itraconazole.